Published in Oncogene on May 26, 2008
Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysis. Nucleic Acids Res (2011) 1.43
Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res (2012) 1.30
The transcription factor p53: not a repressor, solely an activator. Cell Cycle (2014) 1.23
Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. Cancer Res (2009) 1.08
Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene (2008) 1.00
DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol Endocrinol (2010) 0.99
Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex. Oncotarget (2015) 0.98
Deleting the TGF-β receptor attenuates acute proximal tubule injury. J Am Soc Nephrol (2012) 0.95
Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem (2011) 0.95
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer (2016) 0.93
Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res (2010) 0.90
Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One (2013) 0.89
Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol (2008) 0.89
Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia (2015) 0.85
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy. PLoS One (2015) 0.83
Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8. Oncogene (2011) 0.83
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Mol Biol (2012) 0.83
Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. Future Oncol (2010) 0.82
Survivin expression is associated with lens epithelial cell proliferation and fiber cell differentiation. Mol Vis (2012) 0.81
Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. PLoS One (2014) 0.78
Breast cancer stem cells, pathways and therapeutic perspectives 2011. Indian J Surg (2012) 0.77
P130cas is required for TGF-β1-mediated epithelial-mesenchymal transition in lung cancer. Oncol Lett (2014) 0.77
CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin. Cancer Biol Ther (2014) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res (1998) 14.63
Smad transcription factors. Genes Dev (2005) 13.43
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2002) 8.89
Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 8.49
TGF beta signals through a heteromeric protein kinase receptor complex. Cell (1992) 8.12
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
New insights into TGF-beta-Smad signalling. Trends Biochem Sci (2004) 6.13
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 4.52
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 2.97
Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol (2000) 2.84
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene (2000) 2.07
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J (2005) 1.85
Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol (2004) 1.77
Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene (2005) 1.68
Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem (2004) 1.58
Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer (2005) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem (2001) 1.40
p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci (2005) 1.39
Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. EMBO J (1999) 1.39
Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem (2006) 1.24
Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res (1999) 1.24
Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem (2003) 1.23
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res (2007) 1.23
p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem (2000) 1.22
Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res (1996) 1.17
Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res (1994) 1.17
Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem (2004) 1.15
Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol (2004) 1.14
Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev (2005) 1.11
Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem (2001) 1.04
CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res (1997) 1.03
The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene (1999) 1.02
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett (2002) 0.99
Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Cancer Res (2003) 0.89
The differential binding of E2F and CDF repressor complexes contributes to the timing of cell cycle-regulated transcription. Nucleic Acids Res (1997) 0.83
Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry (2008) 6.37
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Mesoderm induction in amphibians: the role of TGF-beta 2-like factors. Science (1988) 2.68
Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci (1991) 2.37
Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32
A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol (2000) 2.17
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest (1989) 2.16
Dynamic evolution of plant mitochondrial genomes: mobile genes and introns and highly variable mutation rates. Proc Natl Acad Sci U S A (2000) 2.13
Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res (1996) 1.97
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol (2012) 1.83
The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell (1992) 1.80
Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest (1993) 1.78
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma (2006) 1.74
Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul (1989) 1.61
Evaluation of 14- and 11-gauge directional, vacuum-assisted biopsy probes and 14-gauge biopsy guns in a breast parenchymal model. Radiology (1997) 1.52
Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol (1991) 1.52
Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol (1992) 1.51
Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer (1990) 1.48
Cited2 modulates TGF-beta-mediated upregulation of MMP9. Oncogene (2006) 1.45
Inhibitory and anti-inflammatory effects of the Helicobacter pylori-derived antimicrobial peptide HPA3NT3 against Propionibacterium acnes in the skin. Br J Dermatol (2014) 1.43
Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr Infect Dis J (1999) 1.42
Intracellular gene transfer in action: dual transcription and multiple silencings of nuclear and mitochondrial cox2 genes in legumes. Proc Natl Acad Sci U S A (1999) 1.40
Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol (1994) 1.36
Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem (1991) 1.34
Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A (2000) 1.32
Identification and characterization of a human cDNA homologous to yeast SKI2. Genomics (1995) 1.27
Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul (1991) 1.27
Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res (1995) 1.26
The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate (1999) 1.25
MSX1 inhibits myoD expression in fibroblast x 10T1/2 cell hybrids. Cell (1995) 1.24
Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res (1999) 1.24
Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol (2001) 1.21
Localization of transforming growth factor-beta 1 in mitochondria of murine heart and liver. Cell Regul (1991) 1.17
Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res (1996) 1.17
In vitro autoradiography reveals predominantly AT1 angiotensin II receptors in rat kidney. Ren Physiol Biochem (1992) 1.13
The anti-apoptotic function of human αA-crystallin is directly related to its chaperone activity. Cell Death Dis (2010) 1.11
Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res (1994) 1.10
Citrobacter freundii: a newly reported cause of pyomyositis. Am J Med Sci (1990) 1.09
MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol (1997) 1.08
Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol (1996) 1.08
Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci U S A (1990) 1.08
Multiple forms of TGF-beta: distinct promoters and differential expression. Ciba Found Symp (1991) 1.07
Liver and bone window settings for soft-copy interpretation of chest and abdominal CT. AJR Am J Roentgenol (2000) 1.07
Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol (2011) 1.07
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry (2012) 1.06
Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant (2003) 1.04
Identification and characterization of a bidirectional promoter from the intergenic region between the human DDX13 and RD genes. Mol Cells (2000) 1.04
Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol (2007) 1.04
Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem (2001) 1.04
Pulmonary sequestration: angioarchitecture evaluated by three-dimensional computed tomography angiography. Thorac Cardiovasc Surg (2010) 1.03
Palliation of malignant bile duct obstruction with metallic biliary endoprostheses: technique, results, and complications. J Vasc Interv Radiol (1992) 1.03
Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem J (1996) 1.01
Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene (2008) 1.00
Transforming growth factor-beta in calf articular cartilage organ cultures: synthesis and distribution. Arch Biochem Biophys (1991) 1.00
Torsion of intraperitoneal renal transplants: imaging appearances. AJR Am J Roentgenol (1998) 0.99
Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death Differ (2009) 0.99
Radiation-induced lung injury in vivo: expression of transforming growth factor-beta precedes fibrosis. Inflammation (1996) 0.99
The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest (1991) 0.98
Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci U S A (1992) 0.98
Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. Growth Factors (1990) 0.98
Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res (2000) 0.98
Percutaneous abdominal and pelvic interventional procedures using CT fluoroscopy guidance. AJR Am J Roentgenol (1999) 0.97
Aberrant TGF-beta production and regulation in metastatic malignancy. Growth Factors (1990) 0.96
The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol (1998) 0.96
ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells. Oncogene (2006) 0.95
Induction and autocrine receptor binding of transforming growth factor-beta 2 during terminal differentiation of primary mouse keratinocytes. Mol Endocrinol (1990) 0.94
Trajectory studies of S(N)2 nucleophilic substitution. 8. Central barrier dynamics for gas phase Cl(-) + CH(3)Cl. J Am Chem Soc (2001) 0.93
Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res (1994) 0.93
Blockade by intravenous losartan of AT1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography. Clin Exp Pharmacol Physiol (1994) 0.92
Isolation and characterization of TGF-beta 2 and TGF-beta 5 from medium conditioned by Xenopus XTC cells. Growth Factors (1990) 0.92
The Drosophila fs(1)Ya protein, which is needed for the first mitotic division, is in the nuclear lamina and in the envelopes of cleavage nuclei, pronuclei, and nonmitotic nuclei. Dev Biol (1994) 0.91
Overamplification of macronuclear linear DNA molecules during prolonged vegetative growth of Oxytricha nova. Gene (1991) 0.91
Mesoderm induction in Xenopus laevis distinguishes between the various TGF-beta isoforms. Growth Factors (1990) 0.91
Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries. J Biol Chem (1990) 0.90
Disseminated trichosporonosis in China. Mycoses (2003) 0.90
Emphysematous gastritis in an immunocompromised host. Clin Imaging (1995) 0.89
Improved purification and yields of RNA by RNeasy. Biotechniques (1996) 0.89
Imaging features of posttransplantation lymphoproliferative disorder in pancreas transplant recipients. AJR Am J Roentgenol (2000) 0.89
Overexpression of FGF-2 modulates fiber cell differentiation and survival in the mouse lens. Development (1997) 0.89
A comparison of remifentanil and fentanyl in patients undergoing surgery for intracranial mass lesions. Anesth Analg (2000) 0.88
Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol (1993) 0.88
Mandibular reconstruction using computer-generated three-dimensional solid models. J Reconstr Microsurg (1994) 0.87
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther (2013) 0.87
Angiotensin II receptor subtypes in the human central nervous system. Brain Res (1995) 0.87
Mutational analyses of fs(1)Ya, an essential, developmentally regulated, nuclear envelope protein in Drosophila. Genetics (1995) 0.87
Regions of Byr4, a regulator of septation in fission yeast, that bind Spg1 or Cdc16 and form a two-component GTPase-activating protein with Cdc16. J Biol Chem (1999) 0.87
Differential regulation of the expression of transforming growth factor-beta mRNAs by growth factors and retinoic acid in chicken embryo chondrocytes, myocytes, and fibroblasts. J Cell Physiol (1992) 0.87
Non-invasive risk assessment of fetal sex chromosome aneuploidy through directed analysis and incorporation of fetal fraction. Prenat Diagn (2014) 0.87
Sonographic evaluation of acute pancreatic transplant rejection: morphology-Doppler analysis versus guided percutaneous biopsy. AJR Am J Roentgenol (1996) 0.87
Assignment of a human putative RNA helicase gene, DDX3, to human X chromosome bands p11.3-->p11.23. Cytogenet Cell Genet (1998) 0.87
Retinoid and androgen regulation of cell growth, epidermal growth factor and retinoic acid receptors in normal and carcinoma rat prostate cells. Mol Cell Endocrinol (1999) 0.86